Announcement of the Board of Directors' resolution
on the appointment of corporate governance officer
Date of events
2022/07/15
To which item it meets
paragraph 8
Statement
1.Type of personnel changed (please enter: spokesperson, acting
spokesperson, important personnel (CEO, COO, CMO, CSO, etc.)
,financial officer, accounting officer, corporate governance officer,
chief information security officer, research and development officer,
chief internal auditor, or designated and non-designated representatives):
corporate governance officer
2.Date of occurrence of the change:2022/07/15
3.Name, title, and resume of the previous position holder:
The duty of corporate governance officer is acting by Zhao-Bei You
4.Name, title, and resume of the new position holder:Zhao-Bei You
5.Type of the change (please enter: "resignation", "position
adjustment", "dismissal", "retirement", "death" or "new
replacement"):new replacement
6.Reason for the change:new replacement
7.Effective date:2022/07/15
8.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Tanvex Biopharma Inc. published this content on 15 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 July 2022 09:33:03 UTC.
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
TANVEX BIOPHARMA, INC. 
